Schiller discusses the high efficacy of HPV vaccine, which is exceptionally good at producing neutralizing antibodies and also benefits from the low mutation rate of HPV. Coming to a better understanding of the efficacy of the HPV vaccine will provide evidence to support single-dose vaccination and aids in the development of new vaccines.
View the full talk with additional resources on our website
Human Papillomavirus (HPV) Vaccines to Prevent Cancer
John Schiller provides an overview of HPV virus and infection, compares the three FDA approved vaccines against HPV, and explains the endpoints used in the clinical trials to prove vaccine efficacy. (Talk recorded in April 2018)
- Part 1: Human Papillomavirus (HPV) Vaccines to Prevent CancerAudience:
- General Public
- Student
- Researcher
- Educators of H. School / Intro Undergrad
- Educators of Adv. Undergrad / Grad
Duration: 00:32:44 - Part 2: Why Do HPV Virus-Like Particle Vaccines Work So Well?Audience:
- General Public
- Student
- Researcher
- Educators of H. School / Intro Undergrad
- Educators of Adv. Undergrad / Grad
Duration: 00:34:26